A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Geoffrey L. Uy, Michael P. Rettig, Ibraheem H. Motabi, Kyle McFarland, Kathryn M. Trinkaus, Lindsay M. Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith E. Stockerl-Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio

Research output: Contribution to journalArticlepeer-review

294 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences